Professor of Pharmacogenetics and Chief Physician Mikko Niemi is leading a research group at the University of Helsinki studying how genes influence the effects, safety and efficacy of drug ingredients. He is also investigating when genetic tests should be considered in drug selection.
“If the genomes of patients were tested systematically, drug treatments could be better tailored and their dosages measured more individually”, says Niemi. Around a dozen genetic tests related to drug treatments are currently available in Finland. The goal of Professor Mikko Niemi is to devise an interpretation algorithm that helps doctors determine the appropriate drug and correct dosage for a patient. Treatments become more effective and side effects are reduced, thus also decreasing the costs. Read more in the article.
ELIXIR is partly funded by the European Commission